INVESTOR RELATIONS
INVESTOR RELATIONS

COMMUNICATION WITH SHAREHOLDERS

 

Pursuant to Article 5(5) of the Law of 15 September 2000 Commercial Companies Code (Journal of Laws of 2000, No. 94, item 1037, as further amended) in the wording in force from 1 January 2020, on the basis of the amendment made by the Act of 30 August 2019 amending the Commercial Companies Code and certain other acts (Journal of Laws of 2019, item 1798), a joint stock company is obliged to maintain its own website and also to place on this website, in places designated for communication with shareholders, the announcements required by law or by the statute from the company.

 

 

 

      CHANGES IN THE MANAGEMENT BOARD OF HELIX IMMUNO-ONCOLOGY S.A.

 

                     On 4 June 2020, the Extraordinary General Meeting of HELIX IMMUNO-ONCOLOGY S.A.adopted resolutions on the

                     changes in the Company's Management Board, entrusting the role of the President of the Management Board as of 5

                     June 2020 to Mr. Ireneusz Fąfara and the role of the Vice-President of the Management Board to Mr. Paweł Wiśniewski.

 

                     Since 5 June 2020, the Company's Management Board has been composed of two members, as follows:

                           1.Ireneusz Fąfara - President of the Management Board

                           2. Paweł Wiśniewski - Vice-President of the Management Board

 

 

 

      SUBMITTING DOCUMENTS TO THE FINANCIAL DOCUMENTS REPOSITORY

                      

                       On 5 February 2020, HELIX IMMUNO-ONCOLOGY S.A. submitted the following documents for the financial year from

                       1 August 2018 to 31 July 2019 to the Financial Documents Repository:

               

                           1. the financial statements,

                           2. the Management Board’s report on company activity,

                           3. the auditor's opinion / audit report on the annual financial statements,

                           4. the resolution on profit distribution or loss coverage,

                           5. the resolution to approve the financial statements.

 

 

ABOUT THE COMPANY

 

      COMPANY

 

                        HELIX IMMUNO-ONCOLOGY S.A. is a subsidiary of Helix BioPharma Corp. The shares of Helix BioPharma Corp. are

                        currently listed on the Toronto Stock Exchange (TSX) under the symbol "HBP". HELIX IMMUNO-ONCOLOGY S.A.

                        completed the process of transformation from a limited liability company into a joint stock company in 2017. This is

                        the first step on the way to the company's debut on the Warsaw Stock Exchange.

 

                        HELIX IMMUNO-ONCOLOGY S.A. actively works on developing innovative products used in cancer therapy. The

                        company's activities in developing potential drugs are based on a technological platform: Tumour Defence Breaker

                        (DOS47), and in particular works on the development of the V-DOS47 molecule, which is used to treat breast

                        cancer and other solid cancers.

 

                        HELIX IMMUNO-ONCOLOGY S.A.

                        Bojkowska 59C Street

                        44-100 Gliwice

                        NIP: 5252547574

                        REGON: 146535883

               share capital: 1,101,950.00 PLN

               entirely paid

               KRS: 0000692806

               District Court in Gliwice

               10th Economic Department of the National Court Register

 

 

      COMPANY AUTHORITIES

 

         

         THE MANAGEMENT BOARD

 

                        Ireneusz Fąfara – President of the Management Board

                        Dr Paweł Wiśniewski - Vice-President of the Management Board

 

 

         SUPERVISORY BOARD

 

                        Prof. Sławomir Majewski - Chairman of the Supervisory Board

                        Dr Heman Chao - Member of the Supervisory Board

                        Andreas Kandziora - Member of the Supervisory Board

 

 

         CONTACT

 

                        Contact for investors:

 

                        Paweł Wiśniewski – Vice-President of the Management Board

                        e-mail: pawel.wisniewski@helixpolska.com

 

                        Please read our Privacy Policy